Diabetic Retinopathy Market Size in the 7MM was found to be USD 126,851 million in 2021

The Diabetic retinopathy market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Diabetic retinopathy symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Diabetic retinopathy symptoms treatment practice/algorithm, market drivers, market barriers, and Diabetic Retinopathy unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key Takeaways from the Diabetic Retinopathy Market

• The total diagnosed Diabetic Retinopathy prevalent population in the 7MM countries was estimated to be 8,033,083 cases in 2020.

• The leading Diabetic Retinopathy Market Companies include Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc, KalVista Pharmaceuticals Ltd, and others

• Promising Diabetic Retinopathy Pipeline Therapies include PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Octreotide Acetate in Microspheres 20 mg, KSI-301, Intravitreal aflibercept injection [IAI], ruboxistaurin, candesartan, Lucentis, and others.

Download report to know which drug is going to capture the maximum market share @ Diabetic Retinopathy Market Size- https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and is associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure.

Diabetic Retinopathy Epidemiology Segmentation in the 7MM
• Total Diabetic Retinopathy Prevalent cases

• Diabetic retinopathy Gender-specific

• Diabetic retinopathy Severity-specific cases

• Diabetic Retinopathy Age-specific cases

Download the report to understand which factors are driving Diabetic Retinopathy Market Trends, click here for Diabetic Retinopathy Market Forecast @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diabetic Retinopathy Market Landscape
The present scenario in the Diabetic Retinopathy therapeutic landscape appears quite confined, limited to laser treatment, eye injections, and anti-VEGF drugs, which are the preferred first line of therapy. The treatments for DR relies heavily on the presence of macular edema.

Diabetic Retinopathy Emerging Drugs

• OPT-302: Opthea Limited
OPT-302 is a first-in-class VEGF-C/D inhibitor. It is a soluble fusion protein comprising immunoglobulin-like domains 1 to 3 of the extracellular domain of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of human immunoglobulin G1 (IgG1) (Opthea, 2019).

OPT-302 is a soluble form of VEGFR-3 which binds ("traps") human VEGF-C and VEGF-D with high affinity, neutralizing their activity by preventing them from binding to both VEGFR-2 and VEGFR-3 (Opthea, 2019).

• RGX 314: Regenxbio
It is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the fluid accumulation in the retina.

• Runcaciguat (BAY 1101042): Bayer
The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy (Hahn et al., 2021).

Learn more about the Diabetic Retinopathy FDA-approved drugs, click here for Diabetic Retinopathy Treatment Market @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diabetic Retinopathy Market Report

• Coverage- 7MM

• Diabetic Retinopathy Companies- Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc, KalVista Pharmaceuticals Ltd, and others

• Diabetic Retinopathy Pipeline Therapies- PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Octreotide Acetate in Microspheres 20 mg, KSI-301, Intravitreal aflibercept injection [IAI], ruboxistaurin, candesartan, Lucentis, and others.

• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy Market Drivers and Barriers

• Diabetic Retinopathy Market Access and Reimbursement, Unmet Needs, Future Perspective

Discover more about Diabetic Retinopathy Drugs in development, click here for Diabetic Retinopathy Market Drugs @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Diabetic Retinopathy Market Overview at a Glance
4. Executive Summary of Diabetic Retinopathy
5. Disease Background and Overview
6. Management and Treatment
7. Epidemiology and Patient Population
8. Patient Journey 1
9. Patient Journey 2
10. Marketed Drugs
11. Emerging Drugs
12. Other Therapy
13. Diabetic Retinopathy: Seven Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

To read more about the Diabetic Retinopathy Market Dynamics of the report, click here for Diabetic Retinopathy Market Barriers and Drivers @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.